Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1975
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: study predating GLP and modern guidelines, limited documentation, but sufficient to derive LD50 value

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1975
Report date:
1975

Materials and methods

Principles of method if other than guideline:
Cyclopentadecanone was administered at the limit dose of 5000 mg/kg bw to 10 rats. Animals were observed for 14 days for mortality and clinical signs.
GLP compliance:
no
Test type:
fixed dose procedure
Limit test:
yes

Test material

Constituent 1
Chemical structure
Reference substance name:
Cyclopentadecanone
EC Number:
207-951-2
EC Name:
Cyclopentadecanone
Cas Number:
502-72-7
Molecular formula:
C15H28O
IUPAC Name:
cyclopentadecanone
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: 75-20

Test animals

Species:
rat
Strain:
not specified
Sex:
not specified

Administration / exposure

Route of administration:
oral: unspecified
Vehicle:
not specified
Doses:
5000 mg/kg bw
No. of animals per sex per dose:
10/dose (sex unspecified)
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Other examinations performed: clinical signs
Statistics:
Not applied.

Results and discussion

Effect levels
Key result
Sex:
not specified
Dose descriptor:
LD50
Effect level:
> 5 000 mg/kg bw
Based on:
test mat.
Mortality:
There were no mortalities over the 14 days observation period.
Clinical signs:
No clinical signs were noted.

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
Based on the results of the study, LD50 of cyclopentadecanone is > 5000 mg/kg bw.
Executive summary:

In a study predating GLP and modern guidelines, cyclopentadecanone has been administered orally to a group of 10 rats of unspecified sex and strain at a limit dose of 5000 mg/kg bw. Animals were observed for 14 days for mortality and clinical signs. There were no deaths, and no clinical signs were noted. Based on the results of the study, the LD50 of cyclopentadecanone exceeds 5000 mg/kg bw.